menu
    • menu
    [{"orgOrder":0,"company":"ATLAS PHARMS LLC","sponsor":"TME Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Noxxon Announces Manufacturing of NOX-A12 Drug Substance and Issuance of Convertible Bonds Under Financing Agreement With Atlas","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Financing","leadProduct":"Emapticap pegol","moa":"CXCL12","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"ATLAS PHARMS LLC","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ATLAS PHARMS LLC \/ Atlas","highestDevelopmentStatusID":"8","companyTruncated":"ATLAS PHAR.."}]

    Find Clinical Drug Pipeline Developments & Deals by Atlas Biologicals

    Menu

    Atlas Biologicals

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            ATLAS PHARMS LLC

                            U.S.A arrow
                            BioProcess International
                            Not Confirmed

                            ATLAS PHARMS LLC

                            U.S.A arrow
                            BioProcess International
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Emapticap pegol,Pembrolizumab,Irinotecan Hydrochloride

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Recipient : TME Pharma

                            Deal Size : Undisclosed

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Noxxon Announces Manufacturing of NOX-A12 Drug Substance and Issuance of Convertible Bonds Under F...

                            Details : As NOXXON advances its pipeline with upcoming start of clinical trials this additional liquidity will focus on manufacturing of NOX-A12 clinical trial supply in anticipation of upcoming clinical trials.

                            Brand Name : NOX-A12

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            June 01, 2021

                            Lead Product(s) : Emapticap pegol,Pembrolizumab,Irinotecan Hydrochloride

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Recipient : TME Pharma

                            Deal Size : Undisclosed

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth